Updates

Plus500 - Forecasts upgraded-yet again

May 2014

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Plus500's Q1 trading update confirmed that it has continued to see accelerating growth and consequently it expects to beat market expectations. Revenues in the quarter were US$60.7m against the previous two sequential quarter's US$50.4m and US$29m. The number of new customers acquired hit a record 20,124 against 19,500 and 12,700, helped by better brand recognition, market volatility and the strong IPO market. The average cost of acquisition (AUAC) and average revenue (ARPU) were US$576 and US$1204, respectively. Broker Liberum has put forward a range of scenarios in an interactive broker note. The base case looks in the bag. Their bull case is something to aim towards and is based on ARPU at $1,108 and AUAC of US$700 for the rest ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Benchmark - Top dog in aquafarming sector

GVC - Special dividend sends shares higher

Plus500 - Exceeds full year forecast in Q1 (June 2020)

Plus500 (March 2020)

Plus500 (July 2014)

Plus500 (March 2014)

Plus500 - 66% forecast upgrade (December 2013)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X